神经退行性疾病中的转谷氨酰胺酶激活
Transglutaminase activation in neurodegenerative diseases.
作者信息
Jeitner Thomas M, Muma Nancy A, Battaile Kevin P, Cooper Arthur Jl
机构信息
Applied Bench Core, Winthrop University Hospital, 222 Station Plaza North, Suite 502, Mineola, NY 11501, USA Tel.: +1 516 663 3455
出版信息
Future Neurol. 2009 Jul 1;4(4):449-467. doi: 10.2217/fnl.09.17.
Abstract
The following review examines the role of calcium in promoting the in vitro and in vivo activation of transglutaminases in neurodegenerative disorders. Diseases such as Alzheimer's disease, Parkinson's disease and Huntington's disease exhibit increased transglutaminase activity and rises in intracellular calcium concentrations, which may be related. The aberrant activation of transglutaminase by calcium is thought to give rise to a variety of pathological moieties in these diseases, and the inhibition has been shown to have therapeutic benefit in animal and cellular models of neurodegeneration. Given the potential clinical relevance of transglutaminase inhibitors, we have also reviewed the recent development of such compounds.
摘要
以下综述探讨了钙在促进神经退行性疾病中谷氨酰胺转移酶的体外和体内激活方面的作用。诸如阿尔茨海默病、帕金森病和亨廷顿病等疾病表现出谷氨酰胺转移酶活性增加以及细胞内钙浓度升高，这两者可能存在关联。钙对谷氨酰胺转移酶的异常激活被认为会在这些疾病中产生多种病理成分，并且在神经退行性变的动物和细胞模型中，抑制作用已显示出具有治疗益处。鉴于谷氨酰胺转移酶抑制剂潜在的临床相关性，我们还综述了此类化合物的最新进展。
相似文献
1
Transglutaminase activation in neurodegenerative diseases.神经退行性疾病中的转谷氨酰胺酶激活
Future Neurol. 2009 Jul 1;4(4):449-467. doi: 10.2217/fnl.09.17.
2
Possible role of the transglutaminases in the pathogenesis of Alzheimer's disease and other neurodegenerative diseases.转谷氨酰胺酶在阿尔茨海默病及其他神经退行性疾病发病机制中的可能作用。
Int J Alzheimers Dis. 2011 Feb 16;2011:865432. doi: 10.4061/2011/865432.
3
Critical role of transglutaminase and other stress proteins during neurodegenerative processes.谷氨酰胺转移酶和其他应激蛋白在神经退行性过程中的关键作用。
Amino Acids. 2010 Feb;38(2):653-8. doi: 10.1007/s00726-009-0428-3. Epub 2009 Dec 5.
4
Possible involvement of transglutaminase-catalyzed reactions in the physiopathology of neurodegenerative diseases.转谷氨酰胺酶催化反应可能参与神经退行性疾病的病理生理学。
Amino Acids. 2013 Jan;44(1):111-8. doi: 10.1007/s00726-011-1081-1. Epub 2011 Sep 22.
5
Transglutaminase inhibition as a possible therapeutical approach to protect cells from death in neurodegenerative diseases.抑制转谷氨酰胺酶作为一种可能的治疗方法，用于保护神经退行性疾病中的细胞免于死亡。
Recent Pat CNS Drug Discov. 2013 Aug;8(2):161-8. doi: 10.2174/15748898113089990001.
6
Pathogenetic Contributions and Therapeutic Implications of Transglutaminase 2 in Neurodegenerative Diseases.转谷氨酰胺酶 2 在神经退行性疾病中的发病机制贡献和治疗意义。
Int J Mol Sci. 2024 Feb 17;25(4):2364. doi: 10.3390/ijms25042364.
7
Transglutaminases as possible therapeutic targets in neurodegenerative diseases.转谷氨酰胺酶作为神经退行性疾病中可能的治疗靶点。
Recent Pat CNS Drug Discov. 2010 Nov;5(3):195-202. doi: 10.2174/157488910793362430.
8
Transglutaminase activity as a possible therapeutical target in neurodegenerative diseases.转谷氨酰胺酶活性作为神经退行性疾病中一个可能的治疗靶点。
Recent Pat CNS Drug Discov. 2013 Dec;8(3):235-42. doi: 10.2174/1574889808666131128105630.
9
Possible physiopathological roles of the transglutaminase activity in the etiopathogenesis of human neurodegenerative diseases.转谷氨酰胺酶活性在人类神经退行性疾病病因学中的可能病理生理作用。
Recent Pat CNS Drug Discov. 2014;9(2):101-9. doi: 10.2174/1574889809666140613114850.
10
Possible physiopathological effects of the transglutaminase activity on the molecular mechanisms responsible for human neurodegenerative diseases.转谷氨酰胺酶活性对人类神经退行性疾病相关分子机制可能产生的生理病理效应。
Recent Pat CNS Drug Discov. 2014;9(2):76-84. doi: 10.2174/1574889809666141111160124.
引用本文的文献
1
The Search for a Universal Treatment for Defined and Mixed Pathology Neurodegenerative Diseases.寻找针对特定和混合病理神经退行性疾病的通用治疗方法。
Int J Mol Sci. 2024 Dec 14;25(24):13424. doi: 10.3390/ijms252413424.
2
Pathogenetic Contributions and Therapeutic Implications of Transglutaminase 2 in Neurodegenerative Diseases.转谷氨酰胺酶 2 在神经退行性疾病中的发病机制贡献和治疗意义。
Int J Mol Sci. 2024 Feb 17;25(4):2364. doi: 10.3390/ijms25042364.
3
Oxidative stress and neuroimmune proteins in a mouse model of autism.自闭症小鼠模型中的氧化应激和神经免疫蛋白。
Cell Stress Chaperones. 2023 Mar;28(2):201-217. doi: 10.1007/s12192-023-01331-2. Epub 2023 Feb 16.
4
Calmodulin Binding Domains in Critical Risk Proteins Involved in Neurodegeneration.参与神经退行性变的关键风险蛋白中的钙调蛋白结合结构域
Curr Issues Mol Biol. 2022 Nov 21;44(11):5802-5814. doi: 10.3390/cimb44110394.
5
Characterisation of a novel cold-adapted calcium-activated transglutaminase: implications for medicine and food processing.一种新型冷适应钙激活转谷氨酰胺酶的特性：对医学和食品加工的启示。
FEBS Open Bio. 2020 Apr;10(4):495-506. doi: 10.1002/2211-5463.12826. Epub 2020 Mar 16.
6
Cystamine and cysteamine as inhibitors of transglutaminase activity .半胱胺和胱胺作为转谷氨酰胺酶活性的抑制剂。
Biosci Rep. 2018 Sep 5;38(5). doi: 10.1042/BSR20180691. Print 2018 Oct 31.
7
Microglia Endocytose Amyloid β Through the Binding of Transglutaminase 2 and Milk Fat Globule EGF Factor 8 Protein.小胶质细胞通过结合转谷氨酰胺酶 2 和乳脂肪球表皮生长因子 8 蛋白内吞淀粉样β。
Neurochem Res. 2018 Jan;43(1):41-49. doi: 10.1007/s11064-017-2284-y. Epub 2017 May 3.
8
Transglutaminases Derived from Astrocytes Accelerate Amyloid β Aggregation.源自星形胶质细胞的转谷氨酰胺酶加速β-淀粉样蛋白聚集。
Neurochem Res. 2017 Aug;42(8):2384-2391. doi: 10.1007/s11064-017-2258-0. Epub 2017 Apr 9.
9
The Different Conformational States of Tissue Transglutaminase Have Opposing Affects on Cell Viability.组织转谷氨酰胺酶的不同构象状态对细胞活力有相反影响。
J Biol Chem. 2016 Apr 22;291(17):9119-32. doi: 10.1074/jbc.M115.699108. Epub 2016 Feb 18.
10
Critical Evaluation of the Changes in Glutamine Synthetase Activity in Models of Cerebral Stroke.脑卒中模型中谷氨酰胺合成酶活性变化的批判性评价
Neurochem Res. 2015 Dec;40(12):2544-56. doi: 10.1007/s11064-015-1667-1. Epub 2015 Aug 2.
本文引用的文献
1
Transglutaminases and neurodegeneration.转谷氨酰胺酶与神经退行性变
J Neurochem. 2009 May;109 Suppl 1(Suppl 1):160-6. doi: 10.1111/j.1471-4159.2009.05843.x.
2
Neuroprotective effects of calmodulin peptide 76-121aa: disruption of calmodulin binding to mutant huntingtin.钙调蛋白肽 76-121aa 的神经保护作用：破坏钙调蛋白与突变 huntingtin 的结合。
Brain Pathol. 2010 Jan;20(1):176-89. doi: 10.1111/j.1750-3639.2008.00258.x. Epub 2009 Mar 10.
3
The Parkinson chimera.帕金森嵌合体。
Neurology. 2009 Feb 17;72(7 Suppl):S2-11. doi: 10.1212/WNL.0b013e318198daec.
4
Alpha-synuclein aggregation and Ser-129 phosphorylation-dependent cell death in oligodendroglial cells.少突胶质细胞中α-突触核蛋白聚集及丝氨酸-129磷酸化依赖性细胞死亡
J Biol Chem. 2009 Apr 10;284(15):10211-22. doi: 10.1074/jbc.M809671200. Epub 2009 Feb 9.
5
Dissecting the mechanisms of tissue transglutaminase-induced cross-linking of alpha-synuclein: implications for the pathogenesis of Parkinson disease.剖析组织转谷氨酰胺酶诱导α-突触核蛋白交联的机制：对帕金森病发病机制的启示
J Biol Chem. 2009 May 8;284(19):13128-42. doi: 10.1074/jbc.M809067200. Epub 2009 Jan 21.
6
Detecting morphologically distinct oligomeric forms of alpha-synuclein.检测α-突触核蛋白形态上不同的寡聚体形式。
J Biol Chem. 2009 Apr 24;284(17):11048-58. doi: 10.1074/jbc.M806559200. Epub 2009 Jan 13.
7
Angiotensin II AT2 receptor oligomers mediate G-protein dysfunction in an animal model of Alzheimer disease.血管紧张素II AT2受体寡聚体在阿尔茨海默病动物模型中介导G蛋白功能障碍。
J Biol Chem. 2009 Mar 6;284(10):6554-65. doi: 10.1074/jbc.M807746200. Epub 2008 Dec 11.
8
Dominant negative AT2 receptor oligomers induce G-protein arrest and symptoms of neurodegeneration.
J Biol Chem. 2009 Mar 6;284(10):6566-74. doi: 10.1074/jbc.M808277200. Epub 2008 Dec 11.
9
Alpha-synuclein misfolding and neurodegenerative diseases.α-突触核蛋白错误折叠与神经退行性疾病
Curr Protein Pept Sci. 2008 Oct;9(5):507-40. doi: 10.2174/138920308785915218.
10
Autoantibodies in gluten ataxia recognize a novel neuronal transglutaminase.麸质共济失调中的自身抗体识别一种新型神经元转谷氨酰胺酶。
Ann Neurol. 2008 Sep;64(3):332-43. doi: 10.1002/ana.21450.
Zotero 插件